Literature DB >> 19657365

Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles.

M Plander1, S Seegers, P Ugocsai, S Diermeier-Daucher, J Iványi, G Schmitz, F Hofstädter, S Schwarz, E Orsó, R Knüchel, G Brockhoff.   

Abstract

Chronic lymphocytic leukemia (CLL) is a malignancy of mature B-lymphocytes that manifests in a variety of clinical courses. The accumulation of CLL-cells is primarily caused by defective apoptosis; however, a higher proliferative capacity has also been found to correlate with poorer prognostic factors. Proliferating CLL-cells are confined to specialized structures called pseudofollicles, which contain CLL-cells, T-lymphocytes, and stromal cells. We established an in vitro model for pseudofollicles to characterize the behavior of CLL-cells in relation to clinical courses with different outcomes. Only CLL-cells from progressive clinical cases were inducible to proliferate by a combination of soluble CD40L/IL-2/IL-10 in co-culture with stromal cells. Proliferating CLL-cells showed a higher and more extensive expression of antigens, which are important in T-B-cell interactions such as CD40, MHC II, and adhesion molecules. IL-4 increased interferon regulatory factor-4 expression and induced a specific immunophenotype, which may imply plasmacytic differentiation. Furthermore, it was shown that co-cultured stromal cells protected CLL-cells from apoptosis. CLL-cells from clinically indolent cases had a far worse survival rate in medium than the cells from poor prognostic cases. Thus, we can assume that not only a different resistance to apoptosis, but also proliferation contributes to the progression of CLL resulting in bone marrow failure with thrombocytopenia and anemia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19657365     DOI: 10.1038/leu.2009.145

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  21 in total

1.  Epigenetic regulation of WNT signaling in chronic lymphocytic leukemia.

Authors:  Lynda B Bennett; Kristen H Taylor; Gerald L Arthur; Farahnaz B Rahmatpanah; Sam I Hooshmand; Charles W Caldwell
Journal:  Epigenomics       Date:  2010-02-01       Impact factor: 4.778

2.  Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).

Authors:  V M Patel; K Balakrishnan; M Douglas; T Tibbitts; E Y Xu; J L Kutok; M Ayers; A Sarkar; R Guerrieri; W G Wierda; S O'Brien; N Jain; H M Stern; V Gandhi
Journal:  Leukemia       Date:  2016-12-26       Impact factor: 11.528

3.  EBI2 overexpression in mice leads to B1 B-cell expansion and chronic lymphocytic leukemia-like B-cell malignancies.

Authors:  Kristine Niss Arfelt; Line Barington; Tau Benned-Jensen; Valentina Kubale; Alexander L Kovalchuk; Viktorija Daugvilaite; Jan Pravsgaard Christensen; Allan Randrup Thomsen; Kristoffer L Egerod; Maria R Bassi; Katja Spiess; Thue W Schwartz; Hongsheng Wang; Herbert C Morse; Peter J Holst; Mette M Rosenkilde
Journal:  Blood       Date:  2016-12-21       Impact factor: 22.113

4.  Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.

Authors:  Kallesh D Jayappa; Craig A Portell; Vicki L Gordon; Brian J Capaldo; Stefan Bekiranov; Mark J Axelrod; L Kyle Brett; Julia D Wulfkuhle; Rosa I Gallagher; Emanuel F Petricoin; Timothy P Bender; Michael E Williams; Michael J Weber
Journal:  Blood Adv       Date:  2017-06-13

5.  TLR-9 and IL-15 Synergy Promotes the In Vitro Clonal Expansion of Chronic Lymphocytic Leukemia B Cells.

Authors:  Patricia K A Mongini; Rashmi Gupta; Erin Boyle; Jennifer Nieto; Hyunjoo Lee; Joanna Stein; Jela Bandovic; Tatjana Stankovic; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Charles C Chu; Nicholas Chiorazzi
Journal:  J Immunol       Date:  2015-07-01       Impact factor: 5.422

6.  Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2.

Authors:  Angela Schulz; Grischa Toedt; Thorsten Zenz; Stephan Stilgenbauer; Peter Lichter; Martina Seiffert
Journal:  Haematologica       Date:  2010-12-06       Impact factor: 9.941

7.  The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Authors:  K Balakrishnan; M Peluso; M Fu; N Y Rosin; J A Burger; W G Wierda; M J Keating; K Faia; S O'Brien; J L Kutok; V Gandhi
Journal:  Leukemia       Date:  2015-04-28       Impact factor: 11.528

8.  Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells.

Authors:  Ryan Wong; Chris Pepper; Paul Brennan; Dirk Nagorsen; Stephen Man; Chris Fegan
Journal:  Haematologica       Date:  2013-06-28       Impact factor: 9.941

9.  BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity.

Authors:  S Cheng; J Ma; A Guo; P Lu; J P Leonard; M Coleman; M Liu; J J Buggy; R R Furman; Y L Wang
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528

10.  The Aurora A and B kinases are up-regulated in bone marrow-derived chronic lymphocytic leukemia cells and represent potential therapeutic targets.

Authors:  Francisco de Paula Careta; Stefania Gobessi; Rodrigo Alexandre Panepucci; Engin Bojnik; Fabio Morato de Oliveira; Daniel Mazza Matos; Roberto P Falcão; Luca Laurenti; Marco A Zago; Dimitar G Efremov
Journal:  Haematologica       Date:  2012-02-13       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.